P-BCMA-101

Drug Profile

P-BCMA-101

Alternative Names: B-cell-maturation antigen-specific CAR T-cells; CARTyrin T cell product; P BCMA 101

Latest Information Update: 12 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Poseida Therapeutics
  • Developer Janssen Biotech; Poseida Therapeutics
  • Class Antineoplastics; CAR-T cell therapies
  • Mechanism of Action B-cell maturation antigen modulators; Immunostimulants; T-cell receptor antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Multiple myeloma
  • Preclinical Solid tumours

Most Recent Events

  • 27 Sep 2017 Phase-I clinical trials in Multiple myeloma (Second-line therapy or greater) in USA (Parenteral) (NCT03288493; 9223569)
  • 22 May 2017 Poseida Therapeutics in-licenses UniDab™ technology from TeneoBio
  • 04 Apr 2017 Preclinical data in Multiple myeloma presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top